The YAP signaling pathway promotes the progression of lymphatic malformations through the activation of lymphatic endothelial cells

Pediatr Res. 2021 Jan;89(1):110-117. doi: 10.1038/s41390-020-0863-0. Epub 2020 Apr 12.

Abstract

Background: To investigate whether the YAP/TAZ (Yes-associated protein/transcriptional coactivator with PDZ binding motif) pathway contributes to the pathogenesis of lymphatic malformations (LMs).

Methods: YAP, TAZ, CTGF (connective tissue growth factor), and Ki-67 were detected in LMs by immunohistochemistry. The colocalization of YAP and Ki-67 was analyzed by double immunofluorescence. Pearson's correlation and cluster analyses were performed to analyze the relationships between these proteins. Human dermal lymphatic endothelial cells (HDLECs) were used for mechanistic investigation. Rat models of LMs were established to investigate the role of the YAP pathway in LM development.

Results: Compared with those in normal skin, the expression levels of YAP, TAZ, CTGF, and Ki-67 were significantly upregulated in lymphatic endothelial cells (LECs) of LMs. Interestingly, YAP and CTGF presented much higher expression levels in infected LMs. In experiments in vitro, lipopolysaccharide (LPS) enhanced the expression of YAP in a concentration- and time-dependent manner via the increased phosphorylation of Erk1/2 (extracellular signal-regulated kinase 1/2). Moreover, the proliferation, invasion, and tubule formation of HDLECs increased significantly in accordance with the activation of the YAP signaling pathway. Furthermore, LM rat models validated that LPS facilitated the development of LMs, which was dependent on the activation of YAP.

Conclusions: The data reveal that activation of the YAP signaling pathway in LECs may play a crucial role in the progression of LMs.

Impact: Compared with that in normal skin, the YAP signaling pathway was activated in LECs of LMs. Inhibiting the YAP signaling pathway attenuated the proliferation, invasion, and tubule formation of HDLECs. Additionally, the activation of the YAP signaling pathway could promote LM development in a rat model. Activation of the YAP signaling pathway in LECs may play a crucial role in the progression of LMs. The YAP signaling pathway was activated in LMs. Inhibition of the YAP signaling pathway could promote regression of the lesions.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adaptor Proteins, Signal Transducing / genetics
  • Adaptor Proteins, Signal Transducing / metabolism*
  • Animals
  • Case-Control Studies
  • Cell Movement
  • Cell Proliferation
  • Cells, Cultured
  • Connective Tissue Growth Factor / metabolism
  • Disease Models, Animal
  • Endothelial Cells / drug effects
  • Endothelial Cells / metabolism*
  • Endothelial Cells / pathology
  • Humans
  • Intracellular Signaling Peptides and Proteins / genetics
  • Intracellular Signaling Peptides and Proteins / metabolism*
  • Ki-67 Antigen / metabolism
  • Lymphangiogenesis* / drug effects
  • Lymphatic Abnormalities / genetics
  • Lymphatic Abnormalities / metabolism*
  • Lymphatic Abnormalities / pathology
  • Lymphatic Abnormalities / prevention & control
  • Lymphatic Vessels / abnormalities
  • Lymphatic Vessels / drug effects
  • Lymphatic Vessels / metabolism*
  • Rats
  • Signal Transduction
  • Transcription Factors / genetics
  • Transcription Factors / metabolism*
  • Transcriptional Coactivator with PDZ-Binding Motif Proteins
  • Verteporfin / pharmacology
  • YAP-Signaling Proteins

Substances

  • Adaptor Proteins, Signal Transducing
  • CCN2 protein, human
  • CCN2 protein, rat
  • Intracellular Signaling Peptides and Proteins
  • Ki-67 Antigen
  • MKI67 protein, human
  • Transcription Factors
  • Transcriptional Coactivator with PDZ-Binding Motif Proteins
  • WWTR1 protein, human
  • WWTR1 protein, rat
  • YAP-Signaling Proteins
  • YAP1 protein, human
  • Yap1 protein, rat
  • Verteporfin
  • Connective Tissue Growth Factor